VITA 34 AG (0NLV.L)

5.98 -0.76 (-11.28%) At close: 08:37AM GMT

VITA 34 AG

Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de

Sector(s): 
Industry: 
Full-time employees: 775

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jakub Julian Baran	Chairman of the Management Board & CEO	N/A	N/A	N/A
Mr. Tomasz Franciszek Baran	VP of the Management Board & Chief Commercial Officer	N/A	N/A	N/A
Mr. Dirk Plaga	CFO & Member of Management Board	N/A	N/A	1965
Santiago Luengo	Managing Director of Secuvita	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

Corporate governance

VITA 34 AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.